SEOUL-SEMICONDUCTOR
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by scientists at the University of Basel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005262/en/
Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight. The two companies have since promoted this natural sunlight spectrum technology through its favorable effects on human well-being and sleep as a key value in the evolution of lighting.
There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” published in the Journal of Lighting and Research Technology published on March 24, 2019.
It is well established that light is one of the strongest control factors for human circadian rhythms, such as the secretion of the sleep promoting hormone melatonin. Thus, optimal lighting condition during daytime are crucial to prevent circadian rhythm disturbances which can lead to sleep disorders and other life-style related diseases. Over the past ten years, there have been related scientific studies in the fields of sleep, chronobiology, physiology, as well as the impact of light quality in elderly care.
According to Prof. Cajochen’s research, LED light sources with the same measured correlated color temperature (CCT) and intensity, but different spectral output, can have different effects on human behavior and physiology. LED light sources with a spectrum close to natural sunlight produced better visual comfort, more alertness, and happier moods in the morning and evening among the test participants, compared to those exposed to conventional spectrum LEDs. The research tested subjects’ visual comfort, circadian physiology, daytime alertness, mood, cognitive performance, and sleep after being exposed to both conventional LED light, and natural spectrum LED light for 49 hours in a laboratory setting.
Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers. Delta EEG activity (0.75–4.5Hz) was significantly higher after daylight-LED than conventional-LED exposure during the post-light exposure night.” [NOTE: Delta EEG (electroencephalogram) measurements record delta waves, the brain waves associated with Stage 3 non-rapid eye movement (NREM) sleep, or “slow-wave sleep” (SWS), and aid in characterizing the depth of sleep.]
By providing the same spectrum as sunlight and in the visible light range, SunLike Series natural spectrum LEDs deliver benefits to human well-being, consistent with the mechanisms of vision that impact both image forming and non-image forming aspects of the eye, as well as the control of circadian rhythms. While the qualities of artificial light have been described primarily with color and intensity thus far, SunLike Series natural spectrum LEDs have introduced light spectrum as another important factor in determining overall light quality.
“This research conducted by the University of Basel suggests another important aspect to the evolving direction of artificial light over the past eighty years. In addition to the properties of energy efficiency and long life, we have added the factor of ‘human well-being’ to modern LED light sources,” said Nam Ki-bum, sales executive vice-president of Seoul Semiconductor. “As the world’s first mass-produced LED devices to achieve natural sunlight quality, SunLike Series LEDs are advancing lighting technology in this important area as we continue to respond to market needs from our customers’ lighting applications.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005262/en/
Contact:
Seoul Semiconductor Inc. North America Andrew Smith Tel: +1 (901) 831-6614 Email: andrew.smith@seoulsemicon.com
Asia and Europe Jeong-hee Kim Tel: +82-70-4391-8311 Email: jeonghee.kim@seoulsemicon.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
